QX008N / Qyuns Therap, Joincare - LARVOL DELTA

A Phase 2 Trial of JKN24011 in COPD (clinicaltrials.gov) - P2 | N=215 | Active, not recruiting | Sponsor: Joincare Pharmaceutical Group Industry Co., Ltd

New P2 trial • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

QX008N, an Anti-TSLP Monoclonal Antibody: Pharmacokinetics, Tolerability, and Immunogenicity in Healthy Chinese Subjects. (PubMed, Clin Transl Sci) - "QX008N exhibited a prolonged half-life (median 30.4 days (range 25.0-47.1) for the 560 mg SC dose), surpassing tezepelumab's 26 days, supporting potential every 6-8 week dosing. Overall, QX008N demonstrated predictable pharmacokinetics, low immunogenicity, and a tolerability profile consistent with single-dose administration of monoclonal antibodies in healthy subjects. These findings provide foundational PK and tolerability data to support subsequent clinical evaluation in patients."

First-in-human • Journal • PK/PD data • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases • TSLP

Beyond inhaled medications: precision medicine and biologic therapies targeting the IL-33/TSLP/type 2 axis in COPD. (PubMed, Front Immunol) - "Emerging drugs such as JKN2401, TQC2731, and tezepelumab demonstrate promising therapeutic potential by modulating these specific inflammatory mediators. This review comprehensively summarizes the pathophysiological roles of these cytokines in COPD, the current progress in biologic drug development targeting these molecules, and the outcomes of recent clinical trials. By elucidating these novel therapeutic avenues, the article aims to provide a theoretical foundation and clinical guidance for precision medicine approaches in COPD management beyond conventional inhaled treatments."

Journal • Review • Chronic Obstructive Pulmonary Disease • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases • IL33 • IL4R • IL5 • TSLP

A Phase 3 Trial of JKN2401 Injection in COPD (clinicaltrials.gov) - P3 | N=888 | Not yet recruiting | Sponsor: Joincare Pharmaceutical Group Industry Co., Ltd

New P3 trial • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Development of a novel humanized anti-TSLP monoclonal antibody, QX008N, and exploration of combination therapy of anti-TSLP antibody and anti-IL-4R antibody. (PubMed, Int Immunopharmacol) - "These results furnish comprehensive preclinical evidence for QX008N as an innovative anti-TSLP therapeutic agent and provide a preliminary rationale for the development of combination therapies that simultaneously target the TSLP and IL-4R signaling pathways."

Combination therapy • Journal • Asthma • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases • IL13